Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

06-09-2023 | Laser | Pediatrics

Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity

Authors: Shumpei Obata, Riko Matsumoto, Maki Iwasa, Masashi Kakinoki, Osamu Sawada, Tomoko Sawada, Yoshitsugu Saishin, Masahito Ohji

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 11/2023

Abstract

Purpose

To evaluate the visual field after anti-vascular endothelial growth factor (VEGF) therapy and laser treatment for retinopathy of prematurity.

Method

Retrospective cohort study. Infants with retinopathy of prematurity treated by anti-VEGF therapy or laser treatment were included in the study. Degrees of visual field in eight directions examined by Goldmann perimeter (intensity, 1000 apostilb; size, V4e = 64 mm²) were compared between the anti-VEGF therapy and laser treatment groups. The visual acuity (VA) and spherical equivalent refraction were also compared between the two groups.

Results

Nine eyes with anti-VEGF therapy and 12 eyes with laser treatment were enrolled in the analysis. The total, upper, nasal upper, nasal, nasal lower, temporal lower, and temporal upper visual fields were significantly wider in the eyes with anti-VEGF therapy than in those with laser treatment (496 vs 416, P = .002; 53 vs 45, P = .008; 56 vs 43, P = .003; 58 vs 39, P < .001; 55 vs 44, P = .01; 72 vs 65, P = .01; and 62 vs 56, P = .03, respectively). The logarithm of the minimum angle of resolution VA tended to be better in the eyes with anti-VEGF therapy than in those with laser treatment (0.01 vs 0.15, P = .06). Eyes with anti-VEGF therapy had significantly lower myopia than those with laser treatment (spherical equivalent refraction: -0.72 vs -5.7, P = .001).

Conclusion

Anti-VEGF therapy may provide a wider visual field, better VA, and less myopia compared with laser treatment.

Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84:77–82. https://doi.org/10.1016/j.earlhumdev.2007.11.009CrossRefPubMed

Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2008) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 115:1058-1064 e1051. https://doi.org/10.1016/j.ophtha.2007.07.028CrossRefPubMed

Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, Lai D, Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2013) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J AAPOS 17:124–128. https://doi.org/10.1016/j.jaapos.2012.10.025CrossRefPubMedPubMedCentral

McLoone E, O’Keefe M, McLoone S, Lanigan B (2007) Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 44:170–173. https://doi.org/10.3928/0191-3913-20070301-10CrossRefPubMed

Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694. https://doi.org/10.1001/archopht.121.12.1684CrossRef

Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615. https://doi.org/10.1056/NEJMoa1007374CrossRefPubMedPubMedCentral

Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, Group B-RC (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(1327):1333. https://doi.org/10.1001/jamaophthalmol.2014.2772CrossRef

Pertl L, Steinwender G, Mayer C, Hausberger S, Poschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10:e0129383. https://doi.org/10.1371/journal.pone.0129383CrossRefPubMedPubMedCentral

Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507–512. https://doi.org/10.1136/bjophthalmol-2013-304109CrossRefPubMed

10.

Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Dastjani Farahani A, Khodabandeh A, Ebrahimi Adib N, Imani M, Khojasteh Jafari H, Riazi-Esfahani H, Hosseinpour J, Zarei M, Ghasemi H, Mirghorbani M, Yaseri M, Davoudi S, Modjtahedi BS (2018) Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retin 2:942–948. https://doi.org/10.1016/j.oret.2018.01.017CrossRef

11.

Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257:1141–1146. https://doi.org/10.1007/s00417-019-04292-4CrossRefPubMed

12.

Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218–226. https://doi.org/10.1016/j.ophtha.2017.08.005CrossRefPubMed

13.

Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M (2017) Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37:97–111. https://doi.org/10.1097/IAE.0000000000001126CrossRefPubMed

14.

International Committee for the Classification of Retinopathy of P (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999. https://doi.org/10.1001/archopht.123.7.991CrossRef

15.

Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP (2017) Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48:255–259. https://doi.org/10.3928/23258160-20170301-10CrossRefPubMed

16.

Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280–283. https://doi.org/10.3928/23258160-20160229-12CrossRefPubMed

17.

Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ (2013) Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS 17:323–325. https://doi.org/10.1016/j.jaapos.2013.01.004CrossRefPubMed

18.

Gundlach BS, Kokhanov A, Altendahl M, Suh SY, Fung S, Demer J, Pineles S, Khitri M, Chu A, Tsui I (2022) Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity. Am J Ophthalmol 238:86–96. https://doi.org/10.1016/j.ajo.2021.11.015CrossRefPubMed

19.

Lee YS, See LC, Chang SH, Wang NK, Hwang YS, Lai CC, Chen KJ, Wu WC (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20–30. https://doi.org/10.1016/j.ajo.2018.05.002CrossRefPubMed

20.

Chen YC, Chen SN (2020) Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol 104:691–696. https://doi.org/10.1136/bjophthalmol-2019-314610CrossRefPubMed

21.

Zhao J, Wu Z, Lam W, Yang M, Chen L, Zheng L, Zhang F, Zeng J, Wang J, Zhang G (2020) Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity. Br J Ophthalmol 104:1556–1560. https://doi.org/10.1136/bjophthalmol-2019-315520CrossRefPubMed

22.

Inoue T, Asaoka R, Hashimoto Y, Kitamoto K, Kitano M, Fujita A, Azuma K, Yamamoto K, Nagahara M, Kadonosono K, Obata R (2021) Does the number of laser applications for ROP treatment influence the degree of myopia? Graefes Arch Clin Exp Ophthalmol 259:317–322. https://doi.org/10.1007/s00417-020-04946-8CrossRefPubMed

23.

Matsumura S, Matsumoto T, Katayama Y, Tomita M, Morikawa H, Itokawa T, Kawakami M, Hori Y (2022) Risk factors for early-onset high myopia after treatment for retinopathy of prematurity. Jpn J Ophthalmol 66:386–393. https://doi.org/10.1007/s10384-022-00921-4CrossRefPubMed

24.

Quinn GE, Fea AM, Minguini N (1991) Visual fields in 4- to 10-year-old children using Goldmann and double-arc perimeters. J Pediatr Ophthalmol Strabismus 28:314–319. https://doi.org/10.3928/0191-3913-19911101-07CrossRefPubMed

Title: Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity
Authors: Shumpei Obata
Riko Matsumoto
Maki Iwasa
Masashi Kakinoki
Osamu Sawada
Tomoko Sawada
Yoshitsugu Saishin
Masahito Ohji
Publication date: 06-09-2023
Publisher: Springer Berlin Heidelberg
Keyword: Laser
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 11/2023
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-023-06227-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity

Abstract

Purpose

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2023

Primary hyperaldosteronism in Acute Central Serous Chorioretinopathy: a real need for screening?

Tilted disc in eyes with fovea plana

The relationship of diabetic retinopathy severity scales with frequency and surface area of diabetic retinopathy lesions

ChatGPT and scientific abstract writing: pitfalls and caution

Cytomegalovirus-positive Posner-Schlossman syndrome: to compare differences in retinal vessel area density between the affected and non-affected eye using optical coherence tomography angiography

The evolution of mechanism of accommodation and a novel hypothesis